https://ptacts.uspto.gov/ptacts/public-informations/petitions/1550005/download-documents?artifactId=170370051
B of A Securities Downgrades Rhythm Pharmaceuticals to Underperform, Lowers Price Target to $17
B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Neutral to Underperform and lowers the price target from $33 to $17.